Diabetes Care, Vol 19, Issue 9 1004-1005, Copyright © 1996 by American Diabetes Association
Glycemic effect of a single high oral dose of the novel sweetener sucralose in patients with diabetes
NH Mezitis, CA Maggio, P Koch, A Quddoos, DB Allison and FX Pi-Sunyer
Division of Endocrinology, Diabetes and Nutrition, St. Luke's-Roosevelt Hospital Center, New York, NY 10025, USA. nhm2@columbia.edu
OBJECTIVE: To examine the effect of a single high oral dose of the novel
noncaloric sweetener sucralose on short-term glucose homeostasis in
patients with IDDM or NIDDM. RESEARCH DESIGN AND METHODS: A total of 13
IDDM and 13 NIDDM patients with glycosylated hemoglobin levels < 10%
completed this double-blind cross-over study. After an overnight fast,
patients were administered opaque capsules containing either 1,000 mg
sucralose or cellulose placebo, followed by a standardized 360-kcal liquid
breakfast. Plasma glucose and serum C-peptide levels were measured over the
next 4 h. RESULTS: Regardless of the type of diabetes, areas under the
curves for changes of plasma glucose and serum C-peptide levels after
sucralose administration were not significantly different from those after
placebo. During test meals with sucralose, one episode of symptomatic
hypoglycemia occurred in each of three IDDM patients, but these episodes
were not considered the result of sucralose administration. CONCLUSIONS:
The present results support the conclusion that sucralose consumption does
not adversely affect short-term blood glucose control in patients with
diabetes.